Literature DB >> 26992705

Unravelling exemestane: From biology to clinical prospects.

Ana Filipa Sobral1, Cristina Amaral2, Georgina Correia-da-Silva3, Natércia Teixeira4.   

Abstract

Aromatase inhibitors (AIs) are anti-tumor agents used in clinic to treat hormone-dependent breast cancer. AIs block estrogens biosynthesis by inhibiting the enzyme aromatase, preventing tumor progression. Exemestane, a third-generation steroidal AI, belongs to this class of drugs and is currently used in clinic to treat postmenopausal women, due to its high efficacy and good tolerability. Here, its pharmacological and biological aspects as well as its clinical applications and comparison to other endocrine therapeutic agents, are reviewed. It is also focused the benefits and risks of exemestane, drawbacks to be overcome and aspects to be explored.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aromatase inhibitors; Clinical trials; Endocrine resistance; Endocrine therapy; Exemestane; Hormone-dependent breast cancer

Mesh:

Substances:

Year:  2016        PMID: 26992705     DOI: 10.1016/j.jsbmb.2016.03.019

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

1.  The effects of cannabinoids in exemestane-resistant breast cancer cells: PS181.

Authors:  C Almeida; T Augusto; G Correia-da-Silva; N Teixeira; C Amaral
Journal:  Porto Biomed J       Date:  2017-09-01

2.  Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.

Authors:  Ludovica Taglieri; Francesca De Iuliis; Anna Giuffrida; Sabrina Giantulli; Ida Silvestri; Susanna Scarpa
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

Review 3.  Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.

Authors:  Yongmei Wang; Fanbo Jing; Haibo Wang
Journal:  Adv Ther       Date:  2022-01-06       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.